8  Review Questions

Open “Answer” below each question to see the answer and explanation. Think it through yourself first before opening it.

8.1 Basic

Q1

What is the “incretin effect”? Explain, including the kind of experiment that demonstrates it.

The phenomenon in which insulin secretion is greater when glucose is given orally than when the same blood glucose profile is reproduced with intravenous glucose. The difference is the incretin effect, which in healthy people is estimated to account for 50–70% of postprandial insulin secretion. (Chapter 1)

Q2

Choose the one incorrect combination below.

  1. GIP — K-cells — duodenum, upper jejunum
  2. GLP-1 — L-cells — ileum, colon
  3. GLP-1 — cut out of proglucagon by PC2
  4. Glucagon — pancreatic α-cells — derived from proglucagon

c. GLP-1 is cut out of proglucagon by PC1/3. What PC2 cuts out is glucagon (pancreatic α-cells). (Chapter 2)

Q3

Why are both GLP-1 and GIP degraded by DPP-4? Explain from the features of their sequences. Also state why they can no longer activate the receptor once degraded.

In both, the second amino acid from the N-terminus is alanine (GLP-1: His-Ala, GIP: Tyr-Ala), making them DPP-4 substrates. DPP-4 cuts off the two N-terminal residues, and in class B1 GPCRs the N-terminal part of the peptide enters the transmembrane domain and activates the receptor, so once that part is lost they can barely activate the receptor. (Chapters 2 and 3)

Q4

Describe, in order, the main intracellular signaling pathway of the GLP-1 receptor from the receptor to insulin exocytosis.

GLP-1R → Gαs → adenylyl cyclase → cAMP↑ → activation of PKA and Epac2 → promotion of K_ATP channel closure, enhancement of Ca²⁺ channel currents, Ca²⁺ release from the ER, and promotion of insulin granule exocytosis. (Chapter 3)

8.2 Applied

Q5

GLP-1 receptor agonists rarely cause hypoglycemia on their own, whereas sulfonylurea (SU) drugs can. Explain this difference using the mechanism of insulin secretion in β-cells.

Insulin secretion occurs via the triggering pathway: glucose metabolism → ATP↑ → K_ATP closure → depolarization → Ca²⁺ influx. SU drugs close K_ATP channels directly, independently of glucose metabolism, so they pull the trigger even during hypoglycemia. GLP-1, on the other hand, only amplifies the triggering pathway via cAMP, so if the trigger is not pulled during hypoglycemia, secretion barely increases. (Chapter 3; Chapter 7, Experiment 3)

Q6

Describe the difference between the actions of GLP-1 and GIP on glucagon secretion from pancreatic α-cells, and discuss the physiological significance of GIP’s action.

GLP-1 suppresses glucagon secretion during hyperglycemia (mainly an indirect action via somatostatin from δ-cells and via β-cells). GIP acts directly on GIPR in α-cells and stimulates glucagon secretion, especially at low-to-normal blood glucose.

Physiologically, this is thought to be a “bidirectional” glucose-stabilizing action that prevents hypoglycemia from insulin alone being released after a low-carbohydrate meal (centered on fat and protein), using insulin and glucagon selectively according to the blood glucose level. (Chapter 4)

Q7

Name two molecular design features that make once-weekly dosing of semaglutide possible.

  1. Ala at position 8 (the second from the N-terminus) was replaced with Aib, conferring DPP-4 resistance
  2. A C18 fatty diacid was attached via a linker to Lys at position 26, so that it binds albumin, making it less susceptible to renal excretion and enzymatic degradation

(Chapter 6)

Q8

Why do long-acting GLP-1 receptor agonists tend to have a relatively weaker effect on postprandial glucose than short-acting ones?

One of the main factors that curbs the postprandial rise in blood glucose is delayed gastric emptying, but this action undergoes tachyphylaxis (attenuation) when GLP-1R is stimulated continuously. With long-acting agents, blood concentrations are always high, so the gastric-emptying delay weakens and the effect is exerted mainly through improvement of fasting glucose (insulin secretion↑, glucagon↓). (Chapter 5)

8.3 Advanced

Q9

What is the “GIP paradox”? Name and explain two possible hypotheses.

The seemingly contradictory phenomenon that both a drug that activates GIPR (tirzepatide) and a drug that blocks it (maridebart cafraglutide, a GIPR-antagonist antibody + GLP-1 peptides) reduce body weight when combined with GLP-1R agonism.

Example hypotheses:

  • Desensitization hypothesis: long-acting GIPR agonists cause receptor desensitization/down-regulation, resulting in a state that is functionally the same as with an antagonist
  • Tissue-specificity hypothesis: the agonist exerts favorable actions in the brain (reduced nausea and appetite suppression in the area postrema) and adipose tissue (improved lipid handling), while the antagonist acts via other tissues/pathways

This has not been settled and remains a topic under investigation. (Chapter 6)

Q10

Body weight tends to increase again after GLP-1 receptor agonists are stopped. Discuss the reason from the viewpoint of the mechanisms of action learned in Chapter 5.

Weight loss with GLP-1RAs is mainly due to appetite suppression in the brain (hypothalamus, brainstem) and satiety from delayed gastric emptying, which work only while the drug keeps stimulating the receptors. Because they do not cure the underlying pathophysiology of obesity itself (the set point of energy homeostasis, compensatory responses that increase appetite, etc.), appetite returns after discontinuation and body weight tends to increase again. In the STEP 1 extension, about 2/3 of the lost weight was reported to have returned within 1 year after stopping. (Chapters 5 and 6)